TransCode Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6 Liberty Sq Pmb 2382, Boston, Massachus...Phone Number
(857) 837-3099Revenue
-Stock Symbol
RNAZIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About TransCode Therapeutics
TransCode Therapeutics is a biotechnology research and development company focused on RNAi oncology solutions. Founded in 2016 and headquartered in Boston, Massachusetts, the company specializes in discovering and developing innovative diagnostics and therapeutics for cancer detection and treatment, with particular emphasis on addressing metastasis. TransCode Therapeutics aims to advance data-driven cancer diagnostics and targeted treatment solutions through their pipeline of RNAi-based technologies. The company operates across multiple locations and serves the healthcare and medical research sectors with their specialized oncology products and services.Explore more
TransCode Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TransCode Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at TransCode Therapeutics
TransCode Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on TransCode Therapeutics recently announced quarterly report
Product Launch: Get notified when TransCode Therapeutics launches new products
Click to see if TransCode Therapeutics had a recent Job posting/layoffs
Check out if TransCode Therapeutics is spiking on competitors!
Check if TransCode Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once TransCode Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at TransCode Therapeutics
Find 2 more new buyers
Compare Similar Companies to TransCode Therapeutics
Compare insights from companies similar to TransCode Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TransCode Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TransCode Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TransCode Therapeutics.
TransCode Therapeutics financials insights
Gather financial insights about TransCode Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Share Placement
$10M
Debt
$25M
TransCode Therapeutics Tech Stack
A closer look at the technologies used by TransCode Therapeutics
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Funding
Project
Spending/Investment, Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Funding
Funding
TransCode Therapeutics News & Media
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the initiation of its Phase 2a clinical trial. The study is to evaluate...TransCode hit by Nasdaq equity deficiency notice | RNAZ 8-K Filing - Stock Titan
TransCode reported $1.25M stockholders’ equity versus Nasdaq’s $2.5M minimum, drawing a deficiency notice. See how planned preferred stock conversion and upcoming votes may affect its listing status.TransCode registers 15.96M resale shares | RNAZ S-3 Registration - Stock Titan
TransCode Therapeutics filed a Form S-3 to register up to 15,955,543 resale shares; issuer receives no proceeds and 916,968 shares were outstanding as of April 29, 2026.TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced cancers, today announced the appointment of Anna Moore, PhD, as Chair of its Scientific...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TransCode Therapeutics
Sign Up For FreeTo access detailed company insights
TransCode Therapeutics is a biotechnology research and development company focused on RNAi oncology solutions. Founded in 2016 and headquartered in Boston, Massachusetts, the company specializes in discovering and developing innovative diagnostics and therapeutics for cancer detection and treatment, with particular emphasis on addressing metastasis... Read More
